ArticleWorld journal of gastrointestinal endoscopy2025
Primary adenocarcinoma from a gastric heterotopic pancreas: A case report.
Article in World journal of gastrointestinal endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant transformation of an ectopic pancreas is exceptionally rare, posing significant diagnostic challenges. As such, there are currently no established management guidelines. We present a rare case of gastric adenocarcinoma arising from ectopic pancreatic tissue and provide a systematic review of previous case reports of adenocarcinomas derived from ectopic pancreas in the stomach, duodenum, and jejunum in the past 20 years. We provide an overview of the clinicopathological characteristics and discuss critical diagnostic and therapeutic considerations. CASE SUMMARY: A 58-year-old female was admitted to our hospital in August 2024 due to elevated carbohydrate antigen 19-9. Relevant examinations found a huge abdominal tumor that was radiologically adherent to both the pancreatic head and the greater curvature of the gastric antrum. A preoperative endoscopic biopsy-confirmed adenocarcinoma, prompting a pancreaticoduodenectomy. Histopathological examination subsequently identified the tumor as an adenocarcinoma originating from a gastric ectopic pancreas. Adjuvant chemotherapy (gemcitabine + capecitabine) commenced on November 13, 2024. After five cycles, surveillance imaging (April 3, 2025) revealed metastatic progression, prompting a transition to second-line therapy (nab-paclitaxel + gemcitabine). The patient is currently undergoing regular chemotherapy and has been followed up regularly, and the condition has not changed significantly compared with before.
conclusionWe hope that our findings will facilitate the clinical recognition of this entity and help to increase knowledge regarding its management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.